Cargando…
The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options
BACKGROUND: Currently, there is no standard context that conforms to the Chinese national framework for evaluating medical decisions regarding the treatment of lung cancer. METHODS: This draft was formulated after a systematic review and a focus group discussion among 20 experts, who were senior phy...
Autores principales: | Cui, Jiu-Wei, Zhou, Qing, Lu, Shun, Cheng, Ying, Wang, Jie, Bai, Ri-Lan, Li, Wen-Qian, Qian, Lei, Chen, Xiao-Yuan, Fan, Yun, Huang, Cheng, Liu, Xiao-Qing, Tu, Hai-Yan, Yang, Jin-Ji, Zhang, Li, Zhou, Jian-Ying, Zhong, Wen-Zhao, Wu, Yi-Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435396/ https://www.ncbi.nlm.nih.gov/pubmed/34584859 http://dx.doi.org/10.21037/tlcr-21-388 |
Ejemplares similares
-
Therapeutic Options in Neuro-Oncology
por: Afonso, Mariana, et al.
Publicado: (2022) -
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
por: Zhong, Wen-Zhao, et al.
Publicado: (2021) -
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
por: Zhong, Wen-Zhao, et al.
Publicado: (2023) -
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
por: Maggie Liu, Si-Yang, et al.
Publicado: (2023) -
Poor prognosis of intra‐tumoural TRBV6‐6 variants in EGFR‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial
por: Chen, Cunte, et al.
Publicado: (2022)